Literature DB >> 28744936

Molecular combing reveals complex 4q35 rearrangements in Facioscapulohumeral dystrophy.

Karine Nguyen1,2, Francesca Puppo1, Stéphane Roche1, Marie-Cécile Gaillard1, Charlène Chaix2, Arnaud Lagarde1, Marjorie Pierret3, Catherine Vovan2, Sylviane Olschwang1,2,4, Emmanuelle Salort-Campana1,5, Shahram Attarian1,5, Marc Bartoli1, Rafaëlle Bernard1,2, Frédérique Magdinier1, Nicolas Levy1,2,6.   

Abstract

Facioscapulohumeral dystrophy (FSHD), one of the most common hereditary neuromuscular disorders, is associated with a complex combination of genetic variations at the subtelomeric 4q35 locus. As molecular diagnosis relying on Southern blot (SB) might be challenging in some cases, molecular combing (MC) was recently developed as an additional technique for FSHD diagnosis and exploration of the genomic organization of the 4q35 and 10q26 regions. In complement to the usual SB, we applied MC in a large cohort of 586 individuals with clinical FSHD. In 332 subjects, the two 4q alleles were normal in size, allowing exclusion of FSHD1 while we confirmed FSHD1 in 230 patients. In 14 patients from 10 families, we identified a recurrent complex heterozygous rearrangement at 4q35 consisting of a duplication of the D4Z4 array and a 4qA haplotype, irresolvable by the SB technique. In five families, we further identified variations in the SMCHD1 gene. Impact of the different mutations was tested using a minigene assay and we analyzed DNA methylation after sodium bisulfite modification and NGS sequencing. We discuss the involvement of this rearrangement in FSHD since all mutations in SMCHD1 are not associated with D4Z4 hypomethylation and do not always segregate with the disease.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  D4Z4; FSHD; Molecular Combing; SMCHD1; methylation; minigene complementation assay (pCAS)

Mesh:

Substances:

Year:  2017        PMID: 28744936     DOI: 10.1002/humu.23304

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

Review 1.  Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era.

Authors:  Stefania Zampatti; Luca Colantoni; Claudia Strafella; Rosaria Maria Galota; Valerio Caputo; Giulia Campoli; Giulia Pagliaroli; Stefania Carboni; Julia Mela; Cristina Peconi; Stefano Gambardella; Raffaella Cascella; Emiliano Giardina
Journal:  Neurogenetics       Date:  2019-03-25       Impact factor: 2.660

2.  Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Jeroen P Vreijling; Don Henderson; Nienke van der Stoep; Nicol Voermans; Baziel van Engelen; Frank Baas; Sabrina Sacconi; Rabi Tawil; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2018-10-15       Impact factor: 6.150

3.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

Review 4.  Cellular and genomic approaches for exploring structural chromosomal rearrangements.

Authors:  Qing Hu; Elizabeth G Maurais; Peter Ly
Journal:  Chromosome Res       Date:  2020-01-13       Impact factor: 5.239

5.  SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.

Authors:  Richard J L F Lemmers; Nienke van der Stoep; Patrick J van der Vliet; Steven A Moore; David San Leon Granado; Katherine Johnson; Ana Topf; Volker Straub; Teresinha Evangelista; Tahseen Mozaffar; Virginia Kimonis; Natalie D Shaw; Rita Selvatici; Alessandra Ferlini; Nicol Voermans; Baziel van Engelen; Sabrina Sacconi; Rabi Tawil; Meindert Lamers; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2019-06-26       Impact factor: 6.318

6.  CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.

Authors:  Autumn Rieken; Aaron D Bossler; Katherine D Mathews; Steven A Moore
Journal:  Neurology       Date:  2020-12-21       Impact factor: 9.910

7.  Analysis of the 4q35 chromatin organization reveals distinct long-range interactions in patients affected with Facio-Scapulo-Humeral Dystrophy.

Authors:  Marie-Cécile Gaillard; Natacha Broucqsault; Julia Morere; Camille Laberthonnière; Camille Dion; Cherif Badja; Stéphane Roche; Karine Nguyen; Frédérique Magdinier; Jérôme D Robin
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379

8.  FSHD1 Diagnosis in a Russian Population Using a qPCR-Based Approach.

Authors:  Nikolay Vladimirovich Zernov; Anna Alekseevna Guskova; Mikhail Yurevich Skoblov
Journal:  Diagnostics (Basel)       Date:  2021-05-28

Review 9.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

Authors:  Anna Greco; Remko Goossens; Baziel van Engelen; Silvère M van der Maarel
Journal:  Clin Genet       Date:  2020-03-04       Impact factor: 4.438

10.  Clinical application of single-molecule optical mapping to a multigeneration FSHD1 pedigree.

Authors:  Qian Zhang; Xueqin Xu; Lirong Ding; Huanzheng Li; Chengyang Xu; Yuyan Gong; Ying Liu; Ting Mu; Don Leigh; David S Cram; Shaohua Tang
Journal:  Mol Genet Genomic Med       Date:  2019-01-21       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.